DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1476 Centers for Disease Control and Prevention. Guidelines for prevention
and treatment of opportunistic infections in HIVinfected
adults and adolescents MMWR, 2009, 58 (No.
RR-4):1–207. Available at: http://aidsinfo.nih.gov/contentfiles/Adult_OI.pdf.
Accessed December 16, 2009.
Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility
of Streptococcus pneumoniae to fluoroquinolones
in Canada. Canadian Bacterial Surveillance Network. N Engl
J Med, 1999, 341:233–239.
Chocarro A, Gonzalez A, Garcia I. Treatment of tularemia with
ciprofloxacin. Clin Infect Dis, 2000, 31:623.
Cozzarelli NR. DNA gyrase and the supercoiling of DNA.
Science, 1980, 207:953–960.
Edelstein PH, Cianciotto NP. Legionella. In: Mandell, Douglas,
and Bennett’s Principles and Practice of Infectious Diseases,
6th ed. (Mandell GL, Bennett JE, Dolin R, eds.), Churchill
Livingstone, New York, 2005, pp. 2711–2727.
Fihn SD. Acute uncomplicated urinary tract infection in women.
N Engl J Med, 2003, 349:259–266.
Gluckstein D, Ruskin J. Rapid oral desensitization to trimethoprimsulfamethoxazole
(TMP-SMZ): Use in prophylaxis for
Pneumocystis carinii pneumonia in patients with AIDS who
were previously tolerant to TMP-SMZ. Clin Infect Dis, 1995,
20:849–853.
Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N
Engl J Med, 1996, 335:1445–1453.
Halliwell RF, Davey PG, Lambert JJ. Antagonism of GABA A
receptors by 4-quinolones. J Antimicrob Chemother, 1993,
31:457–462.
Hill DR, Ericsson CD, Pearson RD, et al. The practice of travel
medicine: Guidelines by the Infectious Diseases Society of
America. Clin Infect Dis, 2006, 43:1499–1539.
Hitchings GH. A biochemical approach to chemotherapy. Ann
NY Acad Sci, 1961, 23:700–708.
Hooper DC. Quinolones. In: Mandell, Douglas, and Bennett’s
Principles and Practice of Infectious Diseases, 6th ed.
(Mandell GL, Bennett JE, Dolin R, eds.), Churchill
Livingstone, New York, 2005a, pp. 451–467.
Hooper DC. Urinary tract agents: Nitrofurantoin and
methenamine. In: Mandell, Douglas, and Bennett’s Principles
and Practice of Infectious Diseases, 6th ed. (Mandell GL,
Bennett JE, Dolin R, eds.), Churchill Livingstone, New York,
2005b, pp. 473–476.
Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for
the use of antimicrobial agents in neutropenic patients with
cancer. Clin Infect Dis, 2002, 34:730–751.
Lesch JE. The First Miracle Drugs: How the Sulfa Drugs
Transformed Medicine. Oxford University Press, New York,
2007.
Mandell LA. Improved safety profile of newer fluoroquinolone.
In: Fluoroquinolone Antibiotics (Ronald AR, Low DE, eds.),
Birkhauser, Basel, 2003, pp. 73–86.
Medical Letter. Gatifloxacin and moxifloxacin: Two new fluoroquinolones.
Med Lett Drugs Ther, 2000, 42:15–17.
SECTION VII
CHEMOTHERAPY OF MICROBIAL DISEASES
Medical Letter. Gemifloxacin. Med Lett Drugs Ther, 2004, 46:
78–80.
Miedouge M, Hacini J, Grimont F, Watine J. Shiga toxin–producing
Escherichia coli urinary tract infection associated with
hemolytic-uremic syndrome in an adult and possible adverse
effect of ofloxacin therapy. Clin Infect Dis, 2000, 30:395–396.
Mitscher LA, Ma Z. Structure-activity relationships of quinolones.
In: Fluoroquinolone Antibiotics (Ronald AR, Low DE, eds.),
Birkhauser, Basel, 2003, pp. 11–48.
Montoya JG, Kovacs JA, Remington JS. Toxoplasma gondii. In:
Mandell, Douglas, and Bennett’s Principles and Practice of
Infectious Diseases, 6th ed. (Mandell GL, Bennett JE, Dolin R,
eds.), Churchill Livingstone, New York, 2005, 3170–3193.
Newman LM, Wang SA, Ohye RG, et al. The epidemiology of
fluoroquinolone-resistant Neisseria gonorrhoeae in Hawaii,
2001. Clin Infect Dis, 2004, 38:649–654.
Oethinger M, Kern WV, Jellen-Ritter AS, et al. Ineffectiveness of
topoisomerase mutations in mediating clinically significant
fluoroquinolone resistance in Escherichia coli in the absence
of the AcrAB efflux pump. Antimicrob Agents Chemother,
2000, 44:10–13.
Olson RP, Harrell LJ, Kaye KS, Antibiotic Resistance in Urinary
Isolates of E. coli from College Women with Urinary Tract
Infections. Antimicrob Agents Chemother, 2009, 53:
1285–1286.
Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin
therapy and dysglycemia in older adults. N Engl J
Med, 2006, 354:1352–1361.
Sabharwal V, Marchant CD. Fluoroquinolone use in children.
Pediatr Infect Dis J, 2006, 25:257–258.
Schwartz J, Jauregui L, Lettieri J, Bachmann K. Impact of
ciprofloxacin on theophylline clearance and steady-state concentrations
in serum. Antimicrob Agents Chemother, 1988,
32:75–77.
Sheehan G, Chew NSY. The history of quinolones. In:
Fluoroquinolone Antibiotics (Ronald AR, Low DE, eds.),
Birkhauser, Basel, 2003, pp. 1–10.
Swartz MN. Recognition and management of anthrax: An
update. N Engl J Med, 2001, 345:1621–1626.
Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J
Med, 2004, 350:2487–2498.
Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolyticuremic
syndrome after antibiotic treatment of Escherichia coli
O157:H7. N Engl J Med, 2000, 342:1930–1936.
Wortmann GW, Bennett SP. Fatal meningitis due to levofloxacinresistant
Streptococcus pneumoniae. Clin Infect Dis, 1999,
29:1599–1600.
Zinner SH, Mayer KH. Sulfonamides and trimethoprim. In:
Mandell, Douglas, and Bennett’s Principles and Practice of
Infectious Diseases, 6th ed. (Mandell GL, Bennett JE, Dolin R,
eds.), Churchill Livingstone, New York, 2005, pp. 440–443.